US Patent Issued to TRITERPENOID THERAPEUTICS on July 29 for "Methods and compositions for inhibiting the NLRP3 inflammasome and/or LON protease" (Vermont Inventor)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,370,202, issued on July 29, was assigned to TRITERPENOID THERAPEUTICS INC. (Braintree, Mass.).

"Methods and compositions for inhibiting the NLRP3 inflammasome and/or LON protease" was invented by Michael B. Sporn (Tunbridge, Vt.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to methods, compositions, and combinations for inhibiting the NLRP3 inflammasome and/or LON protease as well as methods, compositions, and combinations for treating cancer, particularly blood cancer or brain cancer. In certain aspects, the compositions and combinations include a synthetic triterpenoid, such as 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28...